Akebia Grants Par Pharmaceutical a License for Generic Auryxia

Akebia Therapeutics Inc.’s Keryx Biopharmaceuticals unit settled patent litigation against Endo International’s Par Pharmaceutical Inc., which sought to market a generic version of Auryxia.

Keryx and its licensor Panion & BF Biotech Inc. will grant Par a license to market its generic version of Auryxia in the U.S., beginning on March 20, 2025, or earlier under certain circumstances

Other terms are confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice

Auryxia controls serum phosphorus levels in adult patients with chronic kidney disease on dialysis and was also approved for the treatment of ...